Literature DB >> 4131429

Rifampicin hepatitis. A clinical and histological study.

P J Scheuer, J A Summerfield, S Lal, S Sherlock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4131429     DOI: 10.1016/s0140-6736(74)92381-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

1.  Combined rifampicin and chloramphenicol therapy for Enterobacter osteomyelitis.

Authors:  Y Naveh; A Friedman
Journal:  Postgrad Med J       Date:  1979-10       Impact factor: 2.401

2.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

3.  Rifampicin and cysteamine protect against the mushroom toxin phalloidin.

Authors:  G L Floersheim
Journal:  Experientia       Date:  1974-11-15

4.  Liver glycogen bodies: ground-glass hepatocytes in transplanted patients.

Authors:  Pablo A Bejarano; Monica T Garcia; Maria M Rodriguez; Phillip Ruiz; Andreas G Tzakis
Journal:  Virchows Arch       Date:  2006-09-22       Impact factor: 4.064

Review 5.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 6.  Acute liver injury.

Authors:  I C Talbot
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1975

7.  Rifampicin in non-tuberculous infections.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-25

8.  Hepatic reactions to drugs.

Authors:  S Sherlock
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

Review 9.  Drug-induced cholestasis.

Authors:  H J Zimmerman; J H Lewis
Journal:  Med Toxicol       Date:  1987 Mar-Apr

10.  [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].

Authors:  E Musch; M Eichelbaum; J K Wang; W von Sassen; M Castro-Parra; H J Dengler
Journal:  Klin Wochenschr       Date:  1982-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.